Cybin Archives

Tag Archive for: Cybin

Single Dose Of Next-Gen Psilocybin Shows Significant Reduction In Depression, 20% No Longer Needing Treatment

The interim results show remarkable and rapid reduction in depression symptoms compared to traditional antidepressants three weeks after a single dose of next-generation psilocybin.

Math Over Myth: These Psychedelic Stocks Made Confirmed Bottoms in Q3

Business, Stock Reports

Math over Myth is your weekly update on psychedelic stocks and ETFs, including ATAI, COMPASS, Cybin, GH Research, Mindset, Numinus, and more

Math Over Myth: Weekly Psychedelic Stocks News Roundup

Business, Stock Reports

Get the latest news on psychedelic stocks Cybin, Numinus, MindMed, ATAI, Mindset, Braxia, Tryp, Irwin Naturals, and Revive

Sutterstock

The Real Reason Cybin Bought Entheon’s DMT Clinical Trial

Business, Research, Stock Reports

In a rare move Cybin aquires a phase 1 DMT clinical trial from Entheon Biomedical. CEO Doug Drysdale explains why in a Reddit AMA

Psychedelic Business Spotlight – June 24

This Week in Psychedelic Stocks: Compass Pathways Wins Patent Battle, MindMed Patents Candy Flipping, and More!

Business, News, Stock Reports

This week in psychedelic stock news, there are big patent developments for Compass, MindMed and Numinus.

Psychedelic Business Spotlight – June 17

Business, News, Stock Reports

This week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin moves closer to clinical trials, and more!

Psychedelic Business Spotlight – June 10

Business, Stock Reports

This week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon; Numinus completed the acquisition of Novamind, MindMed's stock is removed from an index; and more!

Shutterstock

5 Next-Generation Psychedelics Entering Clinical Trials This Year

Editorial, Research

Modernized psychedelic medicine is coming, whether you like it or not, so here are five of the most exciting next-generation psychedelics on the horizon.